Finance

Beta
Lists
DMII:NASDAQ
Drugs Made In America Acqustn II Corp
$10.07
+0.09%
(+0.0088) 1D
Jun 3, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DMII...
Open
$10.06
High
$10.07
Low
$10.06
Mkt. cap
641.46M
Avg. vol.
156.52K
Volume
3.52K
P/E ratio
13.64
52-wk high
$10.07
52-wk low
$9.87
EPS
$0.74
Shares outstanding
63.70M
Open
$10.06
High
$10.07
Low
$10.06
Mkt. cap
641.46M
Avg. vol.
156.52K
Volume
3.52K
P/E ratio
13.64
52-wk high
$10.07
52-wk low
$9.87
EPS
$0.74
Shares outstanding
63.70M
News stories
From sources across the web
About Drugs Made In America Acqustn II Corp
CEO-
Employees-
Founded2024
Headquarters-
SectorCapital market
Website-
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
38.07K
155.51K
235.47K
132.03K
Operating expense
38.07K
155.51K
1.05M
102.03K
Total operating expenses
38.07K
155.51K
1.05M
102.03K
Operating income
-38.07K
-155.51K
-1.05M
-102.03K
Other non operating income
-
-
-
-
EBT including unusual items
-38.07K
-46.16K
4.33M
4.34M
EBT excluding unusual items
-38.07K
-46.16K
3.78M
4.34M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-38.07K
-46.16K
4.33M
4.34M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
-
109.36K
4.82M
4.44M
Interest expense
-
-
-
-
Net interest expenses
-
109.36K
4.82M
4.44M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer